Document Detail


Effects of bezafibrate on low HDL-cholesterol in patients with ischaemic cerebrovascular disease: a pilot study.
MedLine Citation:
PMID:  7297756     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Bezafibrate is a new lipid-lowering agent that quite constantly increases low HDL-cholesterol values in hyperlipoproteinaemic patients. The possible role fo HDL-cholesterol as an anti-atherogenic factor has been frequently discussed, mainly in patients with ischaemic heart disease but recently also in ischaemic cerebrovascular disease (ICD). This is the first pilot study in six selected patients suffering from ICD who had at the same time low HDL-cholesterol values (less than or equal to = 1.1 mmol/l) with otherwise normal lipids. After a wash-out period of 2 months duration these patients were treated with 200 mg bezafibrate t.i.d. for 2 months. They were then followed up for another 8 months. Bezafibrate therapy increased HDL-cholesterol (range 45-130%). Eight months after cessation of therapy five patients have returned to pathologically low HDL-levels and the sixth patient also has a relatively low value of 1.2 mmol/l. This small preliminary study cannot, however, provide evidence about the possible beneficial role of increasing HDL-cholesterol in patients with ICD. Further investigations are therefore in progress.
Authors:
L Noring; K G Kjellin; H Ledermann
Related Documents :
21829036 - Arg16gly β2-adrenergic receptor gene polymorphism in japanese patients with aspirin-exa...
22237746 - Acute kidney injury following acute liver failure: potential role of systemic cadmium m...
22245276 - Hyperprolactinaemia and the empty sella.
22673196 - Electrocardiographic changes in therapeutic hypothermia.
22470866 - Vitamin d deficiency in hemodialysis patients.
23018876 - Development of monocytosis in patients with primary myelofibrosis indicates an accelera...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  The Journal of international medical research     Volume:  9     ISSN:  0300-0605     ISO Abbreviation:  J. Int. Med. Res.     Publication Date:  1981  
Date Detail:
Created Date:  1982-01-20     Completed Date:  1982-01-20     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0346411     Medline TA:  J Int Med Res     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  319-23     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Antilipemic Agents / therapeutic use*
Bezafibrate
Cerebral Infarction / blood,  drug therapy*
Cholesterol / blood*
Cholesterol, HDL
Clofibrate / analogs & derivatives*
Clofibric Acid / analogs & derivatives*,  therapeutic use
Humans
Ischemic Attack, Transient / blood,  drug therapy*
Lipoproteins, HDL / blood*
Male
Middle Aged
Chemical
Reg. No./Substance:
0/Antilipemic Agents; 0/Cholesterol, HDL; 0/Lipoproteins, HDL; 41859-67-0/Bezafibrate; 57-88-5/Cholesterol; 637-07-0/Clofibrate; 882-09-7/Clofibric Acid

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Sustained antihypertensive response with Minizide: long-term follow-up in a multicentre study.
Next Document:  Characterization of adenohypophysial polypeptides by two-dimensional gel electrophoresis. II. Sulfat...